{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=11",
    "query": {
      "intervention": "antibody-drug conjugate",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 499,
    "total_pages": 50,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T00:36:38.046Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06619236",
      "title": "Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Rina-S",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 584,
      "start_date": "2025-02-07",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 72,
      "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619236"
    },
    {
      "nct_id": "NCT04829604",
      "title": "ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2 Positive Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ARX788",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ambrx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2021-10-26",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 25,
      "location_summary": "Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04829604"
    },
    {
      "nct_id": "NCT01605318",
      "title": "Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer",
        "Colon Cancer",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Labetuzumab Govitecan (LG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2013-02-12",
      "completion_date": "2017-01-03",
      "has_results": false,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 7,
      "location_summary": "Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Goshen",
          "state": "Indiana"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605318"
    },
    {
      "nct_id": "NCT07428044",
      "title": "A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Non-small Cell Lung Cancer Stage II",
        "Non-Small Cell Lung Cancer Stage IIIA",
        "Non-Small Cell Lung Cancer Stage IIIB"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2026-02-13",
      "completion_date": "2027-02-13",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 9,
      "location_summary": "Ann Arbor, Michigan • Rochester, Minnesota • Basking Ridge, New Jersey + 6 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07428044"
    },
    {
      "nct_id": "NCT04351230",
      "title": "T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "HER2 Positive Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Prognostic Stage IV Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-11-11",
      "completion_date": "2022-02-16",
      "has_results": false,
      "last_update_posted_date": "2022-05-26",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 6,
      "location_summary": "Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more",
      "locations": [
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04351230"
    },
    {
      "nct_id": "NCT01472887",
      "title": "SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "SAR3419",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2012-01",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2018-01-25",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Augusta, Georgia • Boise, Idaho",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01472887"
    },
    {
      "nct_id": "NCT06265727",
      "title": "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "CRB-701",
          "type": "DRUG"
        },
        {
          "name": "Anti-PD-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corbus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 348,
      "start_date": "2024-04-01",
      "completion_date": "2027-01-27",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Duarte, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265727"
    },
    {
      "nct_id": "NCT03725761",
      "title": "Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 31,
      "start_date": "2018-10-24",
      "completion_date": "2027-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 3,
      "location_summary": "New York, New York • Madison, Wisconsin",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03725761"
    },
    {
      "nct_id": "NCT05629585",
      "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dato-DXd",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1174,
      "start_date": "2022-11-28",
      "completion_date": "2030-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 88,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05629585"
    },
    {
      "nct_id": "NCT02614560",
      "title": "A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "vadastuximab talirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 14,
      "start_date": "2015-11",
      "completion_date": "2017-09-14",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-10-15T00:36:38.046Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02614560"
    }
  ]
}